Clinical InvestigationSerum YKL-40 Predicts Adverse Clinical Outcomes in Patients With Chronic Heart Failure
Section snippets
Study Subjects
We examined 121 consecutive patients who admitted to the Yamagata University Hospital for evaluation or treatment of CHF between 2004 and 2007. The clinical diagnosis of heart failure was based on the medical history, physical examination, documentation of left ventricular enlargement or dysfunction by chest x-ray, echocardiography, or left ventriculography. Exclusion criteria were acute coronary syndrome within 3 months preceding admission, inflammatory diseases, renal failure (defined as a
Serum YKL-40 Levels in Patients with CHF
Baseline characteristics of all study subjects are listed in Table 1. Serum YKL-40 levels were significantly higher in patients with CHF than in control subjects (P = .0216). Moreover, as shown in Fig. 1, the concentration of serum YKL-40 level increased with advancing NYHA functional class and was significantly higher in severe CHF patients with NYHA Class III/IV than in control subjects (P < .0001) and mild CHF patients with NYHA Class I/II (P < .0001).
In CHF patients, serum YKL-40 levels
Discussion
In this study, we demonstrated that serum YKL-40 levels were elevated in severe CHF patients with NYHA functional Class III/IV. The patients with adverse events had significantly higher serum YKL-40 levels than event-free ones, and higher levels of YKL-40 were associated with a higher incidence of cardiac events. Moreover, YKL-40 was an independent prognostic factor for cardiac events by the multivariate Cox proportional hazard analysis.
CHF is considered as a condition characterized not only by
Conclusions
Concentration of serum YKL-40 levels was increased in patients with heart failure and was related to the severity of disease. The present study for the first time reported the prognostic role of YKL-40 as an independent risk factor to predict adverse clinical outcomes in patients with CHF.
Disclosures
None.
References (36)
- et al.
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD)
J Am Coll Cardiol
(1996) - et al.
Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure
Am Heart J
(2008) - et al.
Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation
Genomics
(1997) - et al.
Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells
Exp Cell Res
(1999) - et al.
Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease
J Hepatol
(2003) - et al.
gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells
Exp Cell Res
(2003) - et al.
The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation
J Biol Chem
(2006) - et al.
Systemic inflammation in heart failure—the whys and wherefores
Heart Fail Rev
(2006) - et al.
Heart failure
N Engl J Med
(2003) - et al.
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study
Circulation
(2003)
Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart
Circulation
CXC-chemokines, a new group of cytokines in congestive heart failure—possible role of platelets and monocytes
Cardiovasc Res
Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages
Eur J Biochem
Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity
Rheumatology (Oxford)
YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils
Proc Assoc Am Physicians
Regulation of YKL-40 production by human articular chondrocytes
Arthritis Rheum
Serum YKL-40, a new prognostic biomarker in cancer patients?
Cancer Epidemiol Biomarkers Prev
YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis
Clin Diagn Lab Immunol
Cited by (0)
This study was supported in part by Grant-in-aid for Scientific Research (No. 21590935) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and Grants from the Takeda Science Foundation, the Uehara Memorial Foundation, and Fukuda Foundation for Medical Technology.
See page 878 for disclosure information.